ID: ALA5277654

Max Phase: Preclinical

Molecular Formula: C37H44Cl2N6O5S

Molecular Weight: 755.77

Associated Items:

Representations

Canonical SMILES:  CN1CCCN[C@@H](Cc2ccc(S(C)(=N)=O)cc2)CC(=O)N[C@H]2CCc3ccccc3N(CC(=O)N[C@H](Cc3ccc(Cl)c(Cl)c3)CC1=O)C2=O

Standard InChI:  InChI=1S/C37H44Cl2N6O5S/c1-44-17-5-16-41-27(18-24-8-12-29(13-9-24)51(2,40)50)21-34(46)43-32-15-11-26-6-3-4-7-33(26)45(37(32)49)23-35(47)42-28(22-36(44)48)19-25-10-14-30(38)31(39)20-25/h3-4,6-10,12-14,20,27-28,32,40-41H,5,11,15-19,21-23H2,1-2H3,(H,42,47)(H,43,46)/t27-,28+,32-,51?/m0/s1

Standard InChI Key:  RBEMVAOMAZYORX-YCAMTLLZSA-N

Associated Targets(Human)

BCL2/BCL2L11 33 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Induced myeloid leukemia cell differentiation protein Mcl-1 3820 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Induced myeloid leukemia cell differentiation protein Mcl-1/Bcl-2-like protein 11 104 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 755.77Molecular Weight (Monoisotopic): 754.2471AlogP: 4.36#Rotatable Bonds: 5
Polar Surface Area: 151.77Molecular Species: NEUTRALHBA: 7HBD: 4
#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 4#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.07CX Basic pKa: 7.29CX LogP: 2.76CX LogD: 2.51
Aromatic Rings: 3Heavy Atoms: 51QED Weighted: 0.30Np Likeness Score: -0.13

References

1. Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, Keefe AD, Lamb ML, Lan H, Li Y, Ma H, Mlynarski S, Packer MJ, Rawlins PB, Robbins DW, Shen H, Sigel EA, Soutter HH, Su N, Troast DM, Wang H, Wickson KF, Wu C, Zhang Y, Zhao Q, Zheng X, Hird AW..  (2017)  Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.,  (2): [PMID:28197319] [10.1021/acsmedchemlett.6b00464]

Source